pharmaphorum October 23, 2024
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the battle for market share.
The US regulator has cleared Abrysvo for use in adults aged 18 to 59 at risk of RSV-related disease, extending its earlier label, which covered the 60 and over age bracket.
GSK’s market-leading Arexvy shot is currently indicated for people aged 50 and over, while recent entrant mResvia from Moderna can be used in the over-60s only at the moment.
Abrysvo has far and away the broadest indications among any of the three vaccines, as it is also the only...
Today's Sponsors
Today's Sponsor